The Procter & Gamble Company (PG) is scheduled to report its earnings results for the third quarter of 2019 on April 23, before the market opens. The Street expects earnings to increase 4% year-over-year to $1.04 per share. Revenue is estimated to inch up slightly by 0.6% to $16.3 billion.
Looking at the past four quarters, P&G has consistently topped earnings estimates, which provides a sense of optimism. The changing trends in the retail industry have taken a toll on the company’s sales which are moving at a sluggish pace. However, its diverse product portfolio coupled with brand loyalty provide the consumer goods giant with an advantage in this environment.
P&G continues to face pressures from high costs and currency fluctuations. The company has been implementing several measures to improve its products and reduce costs and these efforts are likely to help margins. P&G’s performance could also see a benefit from the various strategic acquisitions it has made over the past couple of months.
For the second quarter of 2019, P&G reported better-than-expected earnings which were up 30% year-over-year. Net sales remained flat at $17.4 billion. The Beauty segment has shown momentum over the past two quarters while the weakness persists in Grooming.
For fiscal 2019, P&G expects organic sales to grow 2-4% and core earnings to increase 3-8%. GAAP diluted net EPS is expected to rise 17-24%.
P&G’s shares have rallied over 35% in the trailing 12-month period and the stock has gained over 16% so far this year.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company
Walgreens Boots Alliance set to report earnings next week. Here’s what to expect
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the drug store chain that is expanding into a diversified healthcare provider, is on a restructuring drive aimed at better aligning the business with
Comments
Comments are closed.